CN100556472C - 分离性输血-设备 - Google Patents

分离性输血-设备 Download PDF

Info

Publication number
CN100556472C
CN100556472C CNB2004800303263A CN200480030326A CN100556472C CN 100556472 C CN100556472 C CN 100556472C CN B2004800303263 A CNB2004800303263 A CN B2004800303263A CN 200480030326 A CN200480030326 A CN 200480030326A CN 100556472 C CN100556472 C CN 100556472C
Authority
CN
China
Prior art keywords
column
app
binding
amyloid
protein
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CNB2004800303263A
Other languages
English (en)
Chinese (zh)
Other versions
CN1867365A (zh
Inventor
弗兰克·马特纳
沃尔特·施米特
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Affiris Forschungs und Entwicklungs GmbH
Original Assignee
Affiris Forschungs und Entwicklungs GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34280361&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN100556472(C) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Affiris Forschungs und Entwicklungs GmbH filed Critical Affiris Forschungs und Entwicklungs GmbH
Publication of CN1867365A publication Critical patent/CN1867365A/zh
Application granted granted Critical
Publication of CN100556472C publication Critical patent/CN100556472C/zh
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Images

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
    • A61M1/34—Filtering material out of the blood by passing it through a membrane, i.e. hemofiltration or diafiltration
    • A61M1/3472—Filtering material out of the blood by passing it through a membrane, i.e. hemofiltration or diafiltration with treatment of the filtrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
    • A61M1/34—Filtering material out of the blood by passing it through a membrane, i.e. hemofiltration or diafiltration
    • A61M1/3472—Filtering material out of the blood by passing it through a membrane, i.e. hemofiltration or diafiltration with treatment of the filtrate
    • A61M1/3486—Biological, chemical treatment, e.g. chemical precipitation; treatment by absorbents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
    • A61M1/36—Other treatment of blood in a by-pass of the natural circulatory system, e.g. temperature adaptation, irradiation ; Extra-corporeal blood circuits
    • A61M1/3679—Other treatment of blood in a by-pass of the natural circulatory system, e.g. temperature adaptation, irradiation ; Extra-corporeal blood circuits by absorption
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • General Health & Medical Sciences (AREA)
  • Vascular Medicine (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Anesthesiology (AREA)
  • Molecular Biology (AREA)
  • Chemical & Material Sciences (AREA)
  • Cell Biology (AREA)
  • Urology & Nephrology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Cardiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biodiversity & Conservation Biology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • External Artificial Organs (AREA)
CNB2004800303263A 2003-09-12 2004-09-13 分离性输血-设备 Expired - Fee Related CN100556472C (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
AT0144403A AT413336B (de) 2003-09-12 2003-09-12 Apherese-vorrichtung
ATA1444/2003 2003-09-12

Publications (2)

Publication Number Publication Date
CN1867365A CN1867365A (zh) 2006-11-22
CN100556472C true CN100556472C (zh) 2009-11-04

Family

ID=34280361

Family Applications (1)

Application Number Title Priority Date Filing Date
CNB2004800303263A Expired - Fee Related CN100556472C (zh) 2003-09-12 2004-09-13 分离性输血-设备

Country Status (15)

Country Link
US (2) US7935252B2 (enExample)
EP (1) EP1663347B1 (enExample)
JP (1) JP4509113B2 (enExample)
CN (1) CN100556472C (enExample)
AT (2) AT413336B (enExample)
AU (1) AU2004271651B2 (enExample)
CA (1) CA2538305C (enExample)
CY (1) CY1107911T1 (enExample)
DE (1) DE502004005851D1 (enExample)
DK (1) DK1663347T3 (enExample)
ES (1) ES2298789T3 (enExample)
HR (1) HRP20080090T3 (enExample)
PL (1) PL1663347T3 (enExample)
PT (1) PT1663347E (enExample)
WO (1) WO2005025651A1 (enExample)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004056318A2 (en) 2002-12-19 2004-07-08 New York University Method for treating amyloid disease
AT500483B1 (de) * 2004-07-13 2006-01-15 Mattner Frank Dr Set zur vorbeugung oder behandlung der alzheimer'schen erkrankung
AT501621A1 (de) * 2005-03-15 2006-10-15 Mattner Frank Dr Zusammensetzungen zur verwendung bei der vorbeugung und behandlung der alzheimer- erkrankung
ES2332846B1 (es) * 2007-10-26 2010-07-08 Grifols, S.A. Utilizacion de albumina humana terapeutica para la preparacion de un medicamento para el tratamiento de pacientes afectados por desordenes cognitivos.
US20110123819A1 (en) * 2007-12-21 2011-05-26 Ge Healthcare Bio-Sciences Ab Method for sterilization of chemically activated solid support materials
EP2320987A1 (en) * 2008-07-29 2011-05-18 Medtronic, Inc. Apheresis of a target molecule from cerebrospinal fluid
US20100158893A1 (en) * 2008-12-19 2010-06-24 Baxter International Inc. Systems and methods for obtaining immunoglobulin from blood
CN104274875A (zh) * 2008-12-22 2015-01-14 学校法人藤田学园 Aβ 除去材料、Aβ 除去器和Aβ 除去系统
US20110033463A1 (en) * 2009-08-06 2011-02-10 Medtronic, Inc. Apheresis, administration of agent, or combination thereof
EP2497828A1 (en) * 2011-03-07 2012-09-12 Charité - Universitätsmedizin Berlin Use of aptamers in therapy and/or diagnosis of autoimmune diseases
ES2496341T3 (es) 2011-10-04 2014-09-18 Affiris Ag Procedimiento para detectar anticuerpos Aß-específicos en una muestra biológica
US9717841B2 (en) 2012-09-11 2017-08-01 Gary L. McNeil Closed-circuit device and methods for isolation, modification, and re-administration of specific constituents from a biological fluid source
US10053518B2 (en) * 2014-07-10 2018-08-21 Affiris Ag Substances and methods for the use in prevention and/or treatment in Huntington's disease
EP3166966A1 (en) 2014-07-10 2017-05-17 Affiris AG Substances and methods for the use in prevention and/or treatment in huntington's disease
WO2019023247A1 (en) 2017-07-25 2019-01-31 Immutics, Inc. TREATMENT OF CANCER BY BLOCKING THE INTERACTION OF TIM-3 AND ITS LIGAND
EP3918323A4 (en) 2019-01-30 2022-12-28 TrueBinding, Inc. ANTI-GAL3 ANTIBODIES AND USES THEREOF
GB201904810D0 (en) * 2019-04-05 2019-05-22 Cynapsedx Ltd The treatment of protein aggregation diseases
WO2021242776A2 (en) 2020-05-26 2021-12-02 Truebinding, Inc. Methods of treating inflammatory diseases by blocking galectin-3

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4409105A (en) * 1980-12-18 1983-10-11 Asahi Kasei Kogyo Kabushiki Kaisha Dried, sterilized, gamma-globulin-fixed column and a process for preparing the same
US4770774A (en) * 1985-09-19 1988-09-13 Toray Industries, Inc. Column for removing β2 -microglobulin
US5216127A (en) * 1987-11-20 1993-06-01 Kanegafuchi Kagaku Kogyo Kabushiki Kaisha Adsorbent for serum amyloid protein
WO2003051374A2 (en) * 2001-12-17 2003-06-26 New York State Office Of Mental Health SEQUESTRATION OF Aβ IN THE PERIPHERY IN THE ABSENCE OF IMMUNOMODULATING AGENT AS A THERAPEUTIC APPROACH FOR THE TREATMENT OR PREVENTION OF BETA-AMYLOID RELATED DISEASES
WO2004056318A2 (en) * 2002-12-19 2004-07-08 New York University Method for treating amyloid disease

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH01171638A (ja) * 1987-12-25 1989-07-06 Kanegafuchi Chem Ind Co Ltd 血清アミロイドａ蛋白用吸着体
DE3880647T2 (de) * 1987-11-20 1993-11-18 Kanegafuchi Chemical Ind Sorbentmittel für Serum-Amyloid-Proteine.
US5604102A (en) * 1992-04-15 1997-02-18 Athena Neurosciences, Inc. Methods of screening for β-amyloid peptide production inhibitors
JPH06104122A (ja) 1992-09-21 1994-04-15 Matsushita Electric Ind Co Ltd ロータリートランス
AU691297B2 (en) * 1994-05-13 1998-05-14 Miltenyi Biotec Gmbh Sterile and pyrogen-free columns coupled to protein for binding and removal of substances from blood
DE19549420A1 (de) * 1995-04-27 1997-09-18 Braun Melsungen Ag Verfahren zur simultanen extrakorporalen Elimination von Tumor-Nekrose Faktor alpha (TNF alpha) und bakteriellen Lipopolysacchariden (LPS) aus Vollblut oder/und Blutplasma
US5868936A (en) * 1996-06-20 1999-02-09 Baxter International Inc. Affinity membrane system and method of using same
US6787523B1 (en) * 1997-12-02 2004-09-07 Neuralab Limited Prevention and treatment of amyloidogenic disease
WO2001062801A2 (en) 2000-02-24 2001-08-30 Washington University Humanized antibodies that sequester amyloid beta peptide
TWI238251B (en) * 2000-07-13 2005-08-21 Anawrhta Biotech Co Ltd In-vitro adsorbing device using immunity
AT413945B (de) * 2003-01-14 2006-07-15 Mattner Frank Dr Impfstoff für die alzheimer-krankheit
AT413946B (de) * 2004-07-13 2006-07-15 Mattner Frank Dr Impfstoff gegen die alzheimer-krankheit
AT500835B1 (de) * 2004-09-13 2007-12-15 Affiris Forschungs & Entwicklungs Gmbh Cholinestertransport-protein-mimotop als atherosklerose-medikament

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4409105A (en) * 1980-12-18 1983-10-11 Asahi Kasei Kogyo Kabushiki Kaisha Dried, sterilized, gamma-globulin-fixed column and a process for preparing the same
US4770774A (en) * 1985-09-19 1988-09-13 Toray Industries, Inc. Column for removing β2 -microglobulin
US5216127A (en) * 1987-11-20 1993-06-01 Kanegafuchi Kagaku Kogyo Kabushiki Kaisha Adsorbent for serum amyloid protein
WO2003051374A2 (en) * 2001-12-17 2003-06-26 New York State Office Of Mental Health SEQUESTRATION OF Aβ IN THE PERIPHERY IN THE ABSENCE OF IMMUNOMODULATING AGENT AS A THERAPEUTIC APPROACH FOR THE TREATMENT OR PREVENTION OF BETA-AMYLOID RELATED DISEASES
WO2004056318A2 (en) * 2002-12-19 2004-07-08 New York University Method for treating amyloid disease

Also Published As

Publication number Publication date
EP1663347B1 (de) 2008-01-02
US20070026029A1 (en) 2007-02-01
AU2004271651A1 (en) 2005-03-24
AT413336B (de) 2006-02-15
PL1663347T3 (pl) 2008-06-30
JP2007504863A (ja) 2007-03-08
JP4509113B2 (ja) 2010-07-21
HRP20080090T3 (hr) 2008-03-31
US7935252B2 (en) 2011-05-03
ES2298789T3 (es) 2008-05-16
DE502004005851D1 (de) 2008-02-14
CN1867365A (zh) 2006-11-22
WO2005025651A1 (de) 2005-03-24
HK1096320A1 (zh) 2007-06-01
ATA14442003A (de) 2005-07-15
AU2004271651B2 (en) 2009-08-06
PT1663347E (pt) 2008-03-28
DK1663347T3 (da) 2008-05-19
ATE382383T1 (de) 2008-01-15
US20110166327A1 (en) 2011-07-07
CA2538305A1 (en) 2005-03-24
CA2538305C (en) 2011-05-24
CY1107911T1 (el) 2013-09-04
EP1663347A1 (de) 2006-06-07

Similar Documents

Publication Publication Date Title
CN100556472C (zh) 分离性输血-设备
AU2005261687B8 (en) Combination therapy for the prevention or treatment of Alzheimer's disease as well as kit therefor
US20060030027A1 (en) Capture and removal of biomolecules from body fluids using partial molecular imprints
CN101443041A (zh) 治疗炎性肠病的方法和装置
EP0313378A2 (en) Methods and compositions for transient elimination of humoral immune antibodies
EP2361645B1 (en) Use of a carrier for removal amyloid beta protein from extracorporeal fluids
US6080404A (en) Materials and methods for removal of substances from fluids
CN114929338A (zh) 通过靶向内源性调控因子增强血脑屏障药物转运
KR101139103B1 (ko) 아페레시스 장치
CN101720231A (zh) 治疗全身性红斑狼疮的肽和治疗全身性红斑狼疮的方法
HK1096320B (zh) 分离性输血-设备
US20070225226A1 (en) C-reactive protein apheresis
Schossee et al. Profile of the single‐use, multiple‐pass protein A adsorber column in immunoadsorption
WO2005025650A1 (de) Apherese-vorrichtung
US11186629B2 (en) Treatment method for Cockayne syndrome
EP2742065B1 (en) Agonistic autoantibodies to the alpha1-adrenergic receptor and the beta2-adrenergic receptor in alzheimer's and vascular dementia
JP7255899B2 (ja) 組織または流体から分子を選択的に除去するためのデバイス
US20180303998A1 (en) Novel Treatment Method for Cockayne Syndrome
CN117794591A (zh) 作为捕获配体的修饰tnf
Azhari et al. Specific removal of paraquat by hemoperfusion through antiparaquat conjugated agarose‐polyacrolein microsphere beads
JPH0611335B2 (ja) 吸着体および除去装置

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1096320

Country of ref document: HK

C14 Grant of patent or utility model
GR01 Patent grant
REG Reference to a national code

Ref country code: HK

Ref legal event code: GR

Ref document number: 1096320

Country of ref document: HK

CF01 Termination of patent right due to non-payment of annual fee
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20091104

Termination date: 20160913